- Conditions
- Hemophilia A
- Interventions
- Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 17
- States / cities
- Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 1,193
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Necrotizing Enterocolitis
- Interventions
- IBP-9414, Placebo
- Drug
- Lead sponsor
- Infant Bacterial Therapeutics
- Industry
- Eligibility
- Up to 48 Hours
- Enrollment
- 2,158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 54
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 44 more
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, cyclophosphamide, mitoxantrone hydrochloride, paclitaxel, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Up to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 41 more
- Conditions
- Endometrial Cancer
- Interventions
- danazol
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 1259
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
- Conditions
- Stage III Colon Cancer
- Interventions
- Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
- Device · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1037
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 723 more
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
- Interventions
- Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
- Conditions
- Cervical Cancer
- Interventions
- oxaliplatin
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
- Conditions
- Heart Failure
- Interventions
- LVAD Implant, Aspirin 100mg, Placebo oral tablet
- Device · Drug
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 41
- States / cities
- Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Medical Chart Review
- Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 2,240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 629
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 405 more
- Conditions
- Hepatitis C, HCV
- Interventions
- Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
- Conditions
- Sickle Cell Disease
- Interventions
- Red Blood Cell, Standard of care
- Biological · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 20
- States / cities
- Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Cardiovascular Disease
- Interventions
- Hemolink (hemoglobin raffimer IV solution)
- Drug
- Lead sponsor
- Hemosol
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 19
- States / cities
- San Francisco, California • Stanford, California • Sarasota, Florida + 14 more
- Conditions
- Ovarian Cancer
- Interventions
- oregovomab
- Drug
- Lead sponsor
- Unither Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 62
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 92
- States / cities
- La Mesa, California • Long Beach, California • Los Angeles, California + 81 more
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 586
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- anamorelin HCl, placebo
- Drug
- Lead sponsor
- Helsinn Therapeutics (U.S.), Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more
- Conditions
- Abdominal Injury, Thoracic Diseases
- Interventions
- Signia™ Stapling System
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Albany, New York • Cary, North Carolina + 3 more
- Conditions
- Parkinson's Disease
- Interventions
- creatine, placebo
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Not listed
- Enrollment
- 1,741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- IVA337, Placebo
- Drug
- Lead sponsor
- Inventiva Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
- Conditions
- Candidiasis, Oral, HIV Infections
- Interventions
- Fluconazole
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 948 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 53
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 28 more
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more
- Conditions
- Type2 Diabetes, Dyslipidemia
- Interventions
- K-877, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 242
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 192 more
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- birinapant, Azacitidine, Placebo
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 46
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 39 more